Latest Period
n/a
Security Snapshot
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) Institutional Ownership
CUSIP: 87184Q206
13F Institutional Holders and Ownership History from Q3 2022 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- SYRS on OTC
- Shares outstanding
- 27,196,692
- SEC-reported price per share
- $0.03
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 87184Q206.
- Latest finished 13F holder period is not available.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 4 to 0 between Q1 2025 and Q2 2025.
- SEC-reported value moved from $12,375 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
87184Q206
Latest holder period
n/a
13F holders
13D/G owners
4
CIK / CUSIP context first
SYRS full holder history
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Syros Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87184Q206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
SYRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avidity Partners Management LP | 7.6% | $61,441 | 2,048,020 | Avidity Partners Management LP | 31 Dec 2024 | |||
| Samsara BioCapital, L.P. | 2.6% | $21,213 | 707,114 | Samsara BioCapital, L.P. | 18 Nov 2024 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2% | $15,957 | 531,914 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Point72 Asset Management, L.P. | 0% | $14.88 | 496 | Point72 Asset Management, L.P. | 31 Dec 2024 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
n/a
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$12,375 | $0.03 | 0 |
| 2025 Q1 | 462,954 | $12,375 | -$1,107,011 | $0.03 | 4 |
| 2024 Q4 | 5,216,797 | $1,195,833 | -$29,973,996 | $0.23 | 42 |
| 2024 Q3 | 18,942,451 | $40,725,621 | -$19,620,718 | $2.15 | 64 |
| 2024 Q2 | 20,382,905 | $105,175,826 | -$2,839,834 | $5.16 | 70 |
| 2024 Q1 | 20,915,564 | $111,896,376 | +$14,554,529 | $5.35 | 74 |
| 2023 Q4 | 17,756,706 | $138,325,248 | +$53,999,700 | $7.79 | 57 |
| 2023 Q3 | 12,136,541 | $47,926,746 | +$6,035,294 | $3.95 | 47 |
| 2023 Q2 | 10,623,066 | $33,463,045 | +$1,179,405 | $3.15 | 52 |
| 2023 Q1 | 10,299,991 | $27,503,267 | -$1,433,959 | $2.67 | 53 |
| 2022 Q4 | 10,562,398 | $37,917,223 | +$7,584,586 | $3.59 | 51 |
| 2022 Q3 | 8,426,635 | $54,262,353 | +$54,259,120 | $6.44 | 41 |